Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

Authors

James P. Steele
James Ficorilli
Shweta Urva (ORCID: https://orcid.org/0000-0002-3681-479X)
William C. Roell (ORCID: https://orcid.org/0000-0002-2062-6217)
Axel Haupt (ORCID: https://orcid.org/0000-0003-4502-0470)
Mallikarjuna Rettiganti
Tamer Coşkun (ORCID: https://orcid.org/0000-0002-2481-133X)
Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
Jorge Alsina‐Fernandez
Kyle W. Sloop (ORCID: https://orcid.org/0000-0001-6748-9929)
Libbey S. O′Farrell (ORCID: https://orcid.org/0000-0002-2825-5270)
Hongchang Qu (ORCID: https://orcid.org/0000-0002-9835-3503)
Edward Pratt (ORCID: https://orcid.org/0000-0003-4449-6231)
Ronan P. Kelly (ORCID: https://orcid.org/0000-0002-1135-7238)
Ajit Regmi
Charles E. Benson

Institutions

Eli Lilly (United States) (US)

Publication Details

Journal: Molecular Metabolism
Published: 2025-12-12
DOI: https://doi.org/10.1016/j.molmet.2025.102298
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

James P. Steele, James Ficorilli, Shweta Urva, William C. Roell et al.

Dec 12, 2025

Molecular Metabolism

Diabetes Treatment and Management

article

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

James P. Steele, James Ficorilli, Shweta Urva, William C. Roell, Axel Haupt, Mallikarjuna Rettiganti, Tamer Coşkun, Kieren J. Mather, Jorge Alsina‐Fernandez, Kyle W. Sloop, Libbey S. O′Farrell, Hongchang Qu, Edward Pratt, Ronan P. Kelly, Ajit Regmi, Charles E. Benson

December 12, 2025article en

Abstract

No abstract available for this paper.

Molecular MetabolismVol. 103

Eli Lilly (United States) (US)

Openalex Percentile: Top 48%

Diabetes Treatment and Management

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.